

EDV-Recherche
negativ
Dat./Parache:

30.12.16

Poststelle (BMJV)

Von:
Gesendet:
An:
Betreff:
Anlagen:

Bundesministerium der Justiz und für Verbraucherschutz	
Abl. III	Ref. 134
23.12.2016 08:19	
Anlagen	Doppel
geheftet	fach

Joerg Thomaier <[redacted]>
Donnerstag, 22. Dezember 2016 15:58
Poststelle (BMJV); Maas, Heiko (Minister)
Joint Industry Letter - Unitary Patent and Unified Patent Court
joint_industry_statement.pdf

Dear Mr Heiko MAAS,

Please find attached a joint letter of pharmaceutical companies and associations. I am writing to you on behalf of the undersigning companies which welcome the confirmation by the UK Government that the UK will proceed with its preparations to ratify the Unified Patent Court (UPC) agreement. We would like to give a clear message in support of the unitary patent system again and urge that it should enter into force as planned and with the broadest possible geographical coverage.

Sincerely yours,
Jörg Thomaier

Dr. Jörg Thomaier
Bayer Intellectual Property GmbH
Creative Campus Monheim
Alfred-Nobel-Straße 10
D-40789 Monheim
Phone: +49 2173 38 [redacted]
Fax: +49 2173 38 [redacted]
E-Mail: [redacted]
Web: <http://www.bayer.com>

III 84

GG	AE	BER	v. Abg.	Abl.			
Bundesministerium der Justiz und für Verbraucherschutz							
Eingang: 23. Dez. 2016							
Ministerbüro							
Min.	PSt J	PSt V	St J	St V	LM	PR	PRÖA

Geschäftsführung: Joerg Thomaier | Michael Reinartz
Sitz der Gesellschaft: Monheim am Rhein | Amtsgericht Düsseldorf, HRB 67604

rdA
ll
6/1

9516-31 900/2016

December 20th, 2016

Joint Industry Letter – Unitary Patent and Unified Patent Court

The undersigned companies and associations in the pharmaceutical sector hereby make the following joint statement regarding the Unitary Patent package, that is the Unitary Patent and the Unified Patent Court.

We welcome the confirmation by the UK Government at the EU Competitiveness Council meeting November 28, 2016, that the UK will proceed with its preparations to ratify the Unified Patent Court (UPC) agreement. This means that the way is paved for the Unitary Patent package to move forward and, after completion of the ratifications by UK and Germany, to enter into operation as planned in 2017.

The pharmaceutical industry is heavily dependent on an effective patent system protecting its innovations for a certain period of time. The introduction of the Unitary Patent and the Unified Patent Court will significantly simplify the patent system in Europe and reduce the costs for obtaining, maintaining and enforcing patents. We support and welcome this reform.

We also welcome the view of many delegations at the Competitiveness Council meeting, that the operationalization of the Unitary Patent package with the broadest possible geographical coverage should be achieved as soon as possible, by the prerequisite ratifications of the UPC agreement.

As noted in user communications on the Unitary Patent Package for the September 29, 2016 Competitiveness Council meeting, the attractiveness of the system would increase with a long-term participation of the United Kingdom.

Therefore, solutions for such inclusiveness should also be considered.

Very truly yours,

The undersigned pharmaceutical companies and associations,



Bayer AG, Germany



**Boehringer
Ingelheim**

Boehringer Ingelheim GmbH,
Germany



novo nordisk®

Novo Nordisk A/S, Denmark



Takeda Pharmaceuticals
International AG, Switzerland



The research-based pharmaceutical industry

Swedish Association of the
Pharmaceutical Industry, Sweden

abbvie

AbbVie Deutschland GmbH & Co.
KG / AbbVie USA

Merck

Merck KGaA, Germany

SANOFI

Sanofi S.A., France



Union Chimique Belge, UCB S.A.,
Belgium

vfa Die forschenden
Pharma-Unternehmen